Alemtuzumab (Campath, MabCampath)

Alemtuzumab at a glance

Alemtuzumab targets a protein called CD52 on certain blood cells. Verified oncology brands include Campath and MabCampath. It is a monoclonal antibody: a laboratory-made protein designed to recognise a particular target. It also reduces normal immune cells, so infection prevention is an essential part of treatment.

This article concerns cancer treatment. Another alemtuzumab product, Lemtrada, is used for multiple sclerosis with different dosing and follow-up arrangements. Information for one product must not automatically replace instructions for another. Brand recognition does not establish local availability or suitability.

The main safety concerns are infusion reactions, reduced blood counts and infections that can continue after treatment ends. Regular tests, preventive medicines and prompt reporting of symptoms help your team manage these risks. Some patients need treatment delays or a different plan; this is a safety decision, not something to manage yourself.

How alemtuzumab works

CD52 sits on the surface of certain cells, including lymphocytes, which are white blood cells involved in immunity. Alemtuzumab attaches to CD52 and helps trigger destruction of those cells through immune mechanisms. Where the relevant cancer cells carry this target, that action can be useful.

It is called targeted therapy because it recognises a particular protein. However, CD52 is also found on healthy cells. Treatment can therefore substantially weaken infection defences. The terms targeted therapy and antibody therapy do not mean that treatment is mild or affects cancer cells alone.

Your team assesses benefit using the appropriate examinations and tests for your illness. Feeling tired after an infusion, having no reaction, or seeing a blood-count change cannot by itself tell you whether treatment has succeeded. Ask which results will be used to judge progress and when you will discuss them.

How your team decides whether it is suitable

The specialist considers your diagnosis, laboratory and pathology results, previous treatment, current symptoms and general health. Tests that identify the characteristics of your abnormal blood cells, including relevant target expression, may inform the decision. There is no single home test or symptom that shows whether alemtuzumab is right for you.

Tell the team about recurrent or current infections, past viral illnesses, immune-system conditions, heart or lung disease, kidney problems and earlier severe reactions to medicines. Mention previous cancer treatments, including any that affected your heart or blood counts. These details can change the monitoring and prevention plan.

You should understand the aim of treatment, the expected appointment pattern, alternatives and the circumstances in which treatment would be interrupted or stopped. Practical concerns matter too: frequent visits, transport, support at home and access to urgent assessment should be discussed before starting.

Canadian MabCampath instructions exclude treatment in people with an active infection, an underlying immune deficiency such as HIV, current or previous progressive multifocal leukoencephalopathy (PML), a known severe allergy to the product, or another active cancer. Tell your specialist about any of these before treatment; the team must check the instructions for your specific product.

Before treatment starts

Blood tests establish your starting blood counts and help assess organ function. Your team reviews infection history and decides which infection screening is needed. Explain any fever, cough, diarrhoea, painful urination, infected wound or recent contact with a contagious illness before attending for treatment. Do not assume a mild illness is irrelevant.

Bring a complete medicine list, including supplements, traditional remedies and occasional medicines. Discuss vaccination plans before the first infusion. If pregnancy is possible, the US label recommends a pregnancy test before treatment; contraception and fertility preservation should also be discussed beforehand.

Confirm the plan for infection-prevention medicines and how to obtain repeat supplies. Ask for written instructions showing which medicines continue after the last infusion. Report allergies to antibiotics or antivirals so that suitable alternatives can be arranged.

Make sure you know your hospital's urgent advice arrangements, including nights and weekends. Keep a treatment summary and any transfusion-alert card with you. If another hospital needs to treat you, staff should know you have received alemtuzumab, even if the course finished some time ago.

How treatment is given

Infusion appointments and increasing the dose

The reviewed Campath and MabCampath oncology products are given into a vein by trained staff. The US product is a 30 mg in 1 mL vial, diluted before infusion. It is not an injection to prepare or administer yourself at home.

The standard US schedule starts with 3 mg daily, then 10 mg daily, increasing only when reactions are sufficiently controlled. It then uses 30 mg on three alternate days each week, such as Monday, Wednesday and Friday. The labelled course lasts 12 weeks including the initial dose increases. This describes one verified schedule, not your individual prescription.

The infusion itself is usually given over two hours. Allow longer for assessment, blood results, preventive medicines and observation. An infusion may be slowed or interrupted if you react. Initial appointments can take much of the day; ask the unit what to expect and arrange transport accordingly.

Medicines before treatment and observation

Staff give medicines such as an antihistamine and paracetamol to reduce reactions. Additional medicines, including a steroid, may be used according to your circumstances. Do not independently add extra paracetamol or other premedication before an appointment without checking the plan.

Your nurse monitors you during treatment. Immediately report shivering, rash, flushing, dizziness, chest or back discomfort, wheezing, breathlessness or swelling of the face or throat. A reaction needs assessment even if a previous infusion was uneventful. The team decides how long you need observation afterwards.

Tell the nurse about pain, burning, redness, swelling or leaking around the line. If you have a longer-term venous catheter, follow the unit's care instructions and promptly report redness, discharge or fever.

Missed appointments, interruptions and handling

Contact the unit if you cannot attend or become unwell before an appointment. Never arrange an extra dose or try to catch up. After an interruption of seven days or longer, the US instructions require restarting at a low dose and gradually increasing again because of reaction risk.

Vomiting does not remove an intravenous dose, so it does not require a replacement infusion. Repeated vomiting still needs advice because of dehydration and difficulty taking preventive medicines. The pharmacy manages refrigerated storage, preparation and disposal; ask for specific instructions if you are ever asked to transport a supplied medicine.

Monitoring during and after treatment

A complete blood count measures red cells, white cells and platelets. The US label specifies weekly checks during treatment, with more frequent tests if counts worsen. Low counts may lead to additional support, treatment interruption or stopping treatment. Do not interpret results or alter appointments without your team's advice.

CD4 cells are a type of infection-fighting lymphocyte. Counts are followed after treatment until recovery to at least 200 cells per microlitre. This is one marker used to guide prevention; it does not mean every part of the immune system has fully recovered. Full recovery can take more than a year in some people.

Cytomegalovirus, or CMV, can become active when immunity is reduced. Monitoring is needed during treatment and for at least two months afterwards. Blood testing may detect activity before symptoms develop. Your team will explain its testing timetable and whether a result requires antiviral treatment or a pause in alemtuzumab.

Other checks depend on symptoms and your health, including kidney or liver tests and heart assessment. Planned examinations and disease-specific tests assess treatment benefit separately from safety blood tests. Keep both kinds of appointment, including follow-up when you feel well.

Common side effects and practical care

Fever, chills and infusion symptoms

Reactions are particularly common early in the course. During an infusion, tell staff immediately rather than waiting for symptoms to settle. At home, fever or shivering may indicate infection; you cannot reliably distinguish infection from an infusion reaction yourself. Contact your hospital promptly.

Tiredness and reduced stamina

Treatment, poor sleep, illness and anaemia can all contribute to fatigue. Plan important activities for when you feel strongest, accept practical help and balance rest with gentle movement if safe. New severe weakness, breathlessness, dizziness or a racing heart should be assessed rather than attributed automatically to tiredness.

Nausea, vomiting and diarrhoea

Take prescribed anti-sickness medicine as directed. Smaller meals and frequent sips can be easier than large meals when you feel nauseated. Tell the team early if you cannot eat, keep fluids down or take your infection-prevention medicines.

Report diarrhoea, especially when persistent, accompanied by fever, blood or abdominal pain, or associated with reduced urine. Infection is one possible cause in someone with reduced immunity. Do not repeatedly use over-the-counter anti-diarrhoea treatment without discussing these symptoms. The team may request stool tests or give fluid replacement.

Skin irritation, discomfort and sleep

Rash, itching and aches can occur. Use gentle skin care and discuss appropriate treatments with your nurse. A rapidly spreading rash, blistering, swelling or breathing difficulty needs urgent assessment. Do not treat an infusion-associated rash as an ordinary skin irritation.

If sleep becomes difficult, record whether symptoms follow infusion days or accompanying medicines. A regular bedtime routine and reducing late caffeine may help. Persistent insomnia or anxiety deserves support, particularly if it affects taking medicines or coping with appointments.

Important side effects and delayed problems

Infections and reactivated viruses

Alemtuzumab can cause serious infections, including infections unusual in people with normal immunity. Preventive treatment is given against Pneumocystis pneumonia, also called PJP or PCP, and herpes viruses. Examples include co-trimoxazole and an antiviral; your prescription may use alternatives.

The US instructions continue these preventive medicines throughout treatment and for at least two months afterwards, and until CD4 counts reach at least 200, whichever takes longer. Do not stop at two months unless your team confirms that both conditions are met. Prevention reduces risk but does not eliminate it.

CMV and Epstein–Barr virus, or EBV, may become active. EBV has been associated with serious liver inflammation. Report fever, swollen glands, unusual exhaustion, yellow skin or eyes, dark urine or new abdominal discomfort. A persistent cough, breathlessness, shingles-like rash or painful swallowing also needs prompt advice.

Low blood counts and abnormal bleeding

Low neutrophils increase infection risk, low red cells cause anaemia, and low platelets make bleeding easier. Occasionally the immune system attacks blood cells, or the bone marrow does not produce enough cells. These can be serious problems requiring urgent tests and treatment.

Report unexplained bruising, tiny red or purple skin spots, nose or gum bleeding, blood in urine or stools, worsening pallor or unusual breathlessness. Use a soft toothbrush and avoid activities likely to cause injury when platelets are low. Severe or uncontrolled bleeding is an emergency.

Heart, lungs, brain and nerves

Serious infusion reactions can affect breathing, blood pressure and the heart. New breathlessness later in treatment may also come from infection or lung inflammation. Chest pain, collapse or severe breathing difficulty needs emergency care.

Postmarketing reports include stroke and damage to arteries in the head or neck. Their frequency cannot be reliably estimated. Sudden weakness on one side, facial drooping, trouble speaking, sudden vision loss or a severe unusual headache or neck pain requires emergency assessment.

A serious brain infection called progressive multifocal leukoencephalopathy, or PML, has been reported. New difficulty thinking, changes in behaviour, worsening balance, weakness or vision problems should be reported urgently, even when they develop gradually. Family members may notice changes first. Alert the infusion team before any further dose. Canadian MabCampath instructions require treatment to be withheld while suspected PML is investigated and stopped if PML is confirmed.

Kidney injury, tumour lysis and other delayed problems

Kidney inflammation can occur months or years after treatment. Report blood in the urine, reduced urine, new swelling or unexplained breathlessness. If you cough up blood, seek emergency care. Do not dismiss these symptoms because infusions have finished.

Tumour lysis syndrome happens when rapid breakdown of abnormal cells disturbs blood chemicals and can damage the kidneys or heart. Your team assesses risk and may prescribe fluids and preventive medicines. Markedly reduced urine, severe weakness, muscle cramps, palpitations or confusion needs urgent assessment.

Other immune problems have been reported, including Graves’ disease, which affects the thyroid, and severe inflammation called haemophagocytic lymphohistiocytosis, or HLH. Their frequency is not reliably known. Persistent fever with marked illness, unexplained bruising or abdominal swelling needs urgent review. Severe persistent abdominal pain may also indicate gallbladder inflammation. These symptoms have several possible causes and should not be self-diagnosed.

Other medicines, supplements and vaccinations

Formal interaction studies with Campath have not been performed. This does not establish that every combination is safe. Other treatments that suppress immunity or blood-cell production may increase problems, and preventive antibiotics or antivirals have their own interactions. Let your pharmacist check the complete list before adding a medicine or supplement.

Do not stop prescribed medicines abruptly. Ask before taking aspirin, anti-inflammatory painkillers or herbal remedies, particularly if platelets are low or kidney function is affected. If an anti-infective causes a rash, vomiting or another problem, contact the team for advice rather than simply abandoning infection prevention.

Live vaccines should not be given without specialist clearance after alemtuzumab. Other vaccines may be appropriate, but protection can be weaker while immunity is suppressed. Discuss routine and travel vaccines with the cancer team and vaccination service. Babies exposed during pregnancy also need specialist advice before live vaccines.

Everyday life during treatment

Wash hands regularly, avoid close contact with people who have contagious infections and use sensible food hygiene. Tell your team promptly about exposure to chickenpox, shingles or another significant infection. Ask which precautions are appropriate for your blood counts and household; you do not need to invent your own isolation rules.

Frequent appointments can disrupt work and caring responsibilities. Consider arranging help on infusion days and a backup plan if you need urgent assessment. Do not drive if dizzy, weak or drowsy from treatment or accompanying antihistamines. Discuss travel before booking, because blood tests and access to suitable medical care remain important after infusions end.

Tell your dentist and other healthcare professionals about alemtuzumab before procedures. Dental treatment may need coordination around blood counts and infection risk. Gentle activity can help maintain function, but avoid contact sports or injury-prone activities when bleeding risk is increased.

Blood transfusions and your alert record

You may need specially treated, irradiated red cells or platelets during and after treatment to prevent a serious transfusion complication. Irradiation does not make the blood radioactive. Carry the alert card or record supplied by your team and remind staff at every hospital that you have received alemtuzumab. Your transfusion service determines how long the requirement applies.

In a life-threatening emergency, lifesaving transfusion must not be delayed while waiting for a particular blood product. Give staff the information promptly and let the emergency and transfusion teams make the safest decision.

Fertility, contraception, pregnancy and breastfeeding

Alemtuzumab may harm a developing baby. If you could become pregnant, discuss effective contraception before starting and report a possible pregnancy promptly. Animal findings suggest fertility may be affected in females and males; the effect and reversibility in people are uncertain. Discuss sperm, egg or embryo preservation before treatment where appropriate.

Regional oncology instructions differ. Current US Campath information specifies contraception for female patients during treatment and for at least three months afterwards. Canadian MabCampath information specifies at least six months for women and men of reproductive potential; its patient leaflet advises two effective methods for those who can become pregnant.

Ask your team to record the methods and end date that apply to your product, partner situation and accompanying treatments. The absence of a male interval in the current US section does not establish that pregnancy precautions are unnecessary. Do not shorten a longer interval prescribed by your team.

Do not breastfeed during treatment or for at least three months after the final dose according to the reviewed US and Canadian information. Confirm with your clinician before restarting, particularly if other medicines require a longer restriction.

After treatment finishes

The last infusion is not the end of safety follow-up. Continue preventive medicines and blood tests for the prescribed period. Keep your CMV monitoring appointments and ask which symptoms require urgent assessment as your immune system recovers. Avoid treating an improved overall blood count as permission to stop prevention.

Keep the treatment and transfusion-alert record available for future care. New urinary changes, bleeding, neurological symptoms or other unexplained illness may still need assessment long afterwards. Oncology follow-up should be tailored to your course; do not substitute a Lemtrada multiple-sclerosis follow-up schedule found online.

Ask for a written summary of ongoing precautions, next assessments and who coordinates care. Returning to normal activities may be gradual. If anxiety about infection or persistent fatigue is restricting daily life, the team can help distinguish problems needing investigation from concerns that may benefit from rehabilitation or emotional support.

Frequently asked questions